Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4401941 | 0.99 | TRPC6 (0.41) | TRPC6TPSAB1KCNH2ALDH1A1HTT | |
| SCHEMBL7019473 | 0.90 | TPSAB1 (0.41) | TRPC6TPSAB1KCNH2ALDH1A1CYP2C9 | |
| SCHEMBL1381851 | 0.89 | TPSAB1 (0.51) | TRPC6TPSAB1KCNH2ALDH1A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL4404743 | 0.89 | TPSAB1 (0.40) | TRPC6TPSAB1KCNH2ALDH1A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL6486065 | 0.88 | TPSAB1 (0.50) | TRPC6TPSAB1KCNH2ALDH1A1CYP2C9 | |
| Hydrochloric Acid SCHEMBL4403389 | 0.88 | TPSAB1 (0.50) | TRPC6TPSAB1KCNH2ALDH1A1CYP2C9 | |
| SCHEMBL27535800 | 0.85 | NAMPT (0.41) | TPSAB1KCNH2ALDH1A1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27500510 | 0.84 | NAMPT (0.41) | TPSAB1KCNH2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1380986 | 0.84 | MGLL (0.39) | TPSAB1KCNH2CYP2C9CYP2C19MEN1 | |
| SCHEMBL7021172 | 0.84 | TPSAB1 (0.53) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4796732-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | claimed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | claimed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | claimed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | claimed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TRPC6 472/4885TPSAB1 4/4885KCNH2 2745/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TRPC6 472/4885TPSAB1 4/4885KCNH2 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.